Cargando…
Prognostic value of circulating proteins in patients undergoing surgery for pancreatic cancer
BACKGROUND: Pancreatic ductal adenocarcinoma (PDAC) is the fourth leading cause of cancer death. Less than 20% of patients are diagnosed with resectable disease. Identifying truly resectable disease is challenging because 20%–40% of the patients subjected to resection are found to have advanced dise...
Autores principales: | Lindgaard, Sidsel C., Sztupinszki, Zsófia, Maag, Emil, Hansen, Carsten P., Chen, Inna M., Johansen, Astrid Z., Hasselby, Jane P., Bojesen, Stig E., Nielsen, Dorte, Johansen, Julia S. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9972037/ https://www.ncbi.nlm.nih.gov/pubmed/36250429 http://dx.doi.org/10.1002/cam4.5240 |
Ejemplares similares
-
Circulating Protein Biomarkers for Prognostic Use in Patients with Advanced Pancreatic Ductal Adenocarcinoma Undergoing Chemotherapy
por: Lindgaard, Sidsel C., et al.
Publicado: (2022) -
Determination of temporal reproducibility and variability of cancer biomarkers in serum and EDTA plasma samples using a proximity extension assay
por: Christensen, Troels D., et al.
Publicado: (2022) -
Development and validation of circulating protein signatures as diagnostic biomarkers for biliary tract cancer
por: Christensen, Troels D., et al.
Publicado: (2022) -
A Randomized Placebo-Controlled Phase 2 Study of Gemcitabine and Capecitabine with or without T-ChOS as Adjuvant Therapy in Patients with Resected Pancreatic Cancer (CHIPAC)
por: Theile, Susann, et al.
Publicado: (2022) -
Protein Signatures and Individual Circulating Proteins, including IL-6 and IL-15, Associated with Prognosis in Patients with Biliary Tract Cancer
por: Christensen, Troels D., et al.
Publicado: (2023)